Product data sheet



MedKoo Cat#: 555674		
Name: GW284543		
CAS: 790186-68-4		
Chemical Formula: C ₂₃ H ₂₀ N ₂ O ₃		
Exact Mass: 372.1474		HN O
Molecular Weight: 372.424		
Product supplied as:	Powder	
Purity (by HPLC):	≥ 98%	
Shipping conditions	Ambient temperature	
Storage conditions:	Powder: -20°C 3 years; 4°C 2 years.	O ~ N
	In solvent: -80°C 3 months; -20°C 2 weeks.	

1. Product description:

GW284543, also known as UNC10225170;, is a potent and selective MEK5 inhibitor with the potential for cancer treatment.

2. CoA, QC data, SDS, and handling instruction

SDS and handling instruction, CoA with copies of QC data (NMR, HPLC and MS analytical spectra) can be downloaded from the product web page under "QC And Documents" section. Note: copies of analytical spectra may not be available if the product is being supplied by MedKoo partners. Whether the product was made by MedKoo or provided by its partners, the quality is 100% guaranteed.

3. Solubility data

Solvent	Max Conc. mg/mL	Max Conc. mM
DMSO	67.0	179.90

4. Stock solution preparation table:

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	2.69 mL	13.43 mL	26.85 mL
5 mM	0.54 mL	2.69 mL	5.37 mL
10 mM	0.27 mL	1.34 mL	2.69 mL
50 mM	0.05 mL	0.27 mL	0.54 mL

5. Molarity Calculator, Reconstitution Calculator, Dilution Calculator

Please refer the product web page under section of "Calculator"

6. Recommended literature which reported protocols for in vitro and in vivo study

In vitro study

1. Vaseva AV, Blake DR, Gilbert TSK, Ng S, Hostetter G, Azam SH, Ozkan-Dagliyan I, Gautam P, Bryant KL, Pearce KH, Herring LE, Han H, Graves LM, Witkiewicz AK, Knudsen ES, Pecot CV, Rashid N, Houghton PJ, Wennerberg K, Cox AD, Der CJ. KRAS Suppression-Induced Degradation of MYC Is Antagonized by a MEK5-ERK5 Compensatory Mechanism. Cancer Cell. 2018 Nov 12;34(5):807-822.e7. doi: 10.1016/j.ccell.2018.10.001. PMID: 30423298; PMCID: PMC6321749.

In vivo study

TBD

7. Bioactivity

Biological target:

GW284543 (UNC10225170) is a selective MEK5 inhibitor.

In vitro activity

UNC10225170 treatment dose-dependently inhibited MEK5, as determined by reductions in pERK5, and decreased endogenous MYC protein (Figure 6C).

Reference: Cancer Cell. 2018 Nov 12;34(5):807-822.e7. doi https://pubmed.ncbi.nlm.nih.gov/30423298/

Product data sheet



In vivo activity

TBD

Note: The information listed here was extracted from literature. MedKoo has not independently retested and confirmed the accuracy of these methods. Customer should use it just for a reference only.